Develop short-course treatments for visceral leishmaniasis in South Asia to replace treatments with severe side effects and growing drug resistance
current phase of drug development
updated 1 Mar 2022
Adoption of new visceral leishmaniasis treatments in South Asia
Policy change for control and elimination of visceral leishmaniasis brings better treatments to patients in Bangladesh, India, and Nepal
In the early 21st century, treatments for visceral leishmaniasis (also known as kala-azar) in South Asia were difficult for patients to take or growing ineffective. Resistance was increasing, including to the oral drug miltefosine. Antimonials such as sodium stibogluconate had lengthy treatment times, difficult treatment administration, and poor tolerability that caused frequent side effects.
In 2010, WHO recommended using new short-course treatments for visceral leishmaniasis in South Asia based on excellent results in Phase III studies. However, more evidence was needed on the safety and effectiveness of using these treatments for in wider populations under field conditions.
DNDi convened a consortium of partners to identify the best combination therapies for South Asia. The consortium conducted a four year-long implementation study in Bangladesh and India (2012 – 2015) to assess the safety, efficacy, and patient adherence of three new treatment options: single-dose liposomal amphotericin B; a paromomycin and miltefosine combination; and a single-dose liposomal amphotericin B and miltefosine combination. The results showed that these treatments are safe and effective, with cure rates above 95%. They also shorten the length of treatment, reduce the risk of resistance, and allow treatment of patients closer to their homes, making it easier for people to complete the full treatment course.
The research provided key evidence for policy changes by the Bangladeshi, Indian, and Nepali Ministries of Health, which made the following recommendations: single-dose liposomal amphotericin B as the first option for treatment of visceral leishmaniasis, and a combination of paromomycin and miltefosine as the second option.
- Indication: Visceral leishmaniasis in Asia
- Dosage: First option: single-dose liposomal amphotericin B given as an intravenous infusion; Second option: paromomycin and miltefosine, both daily for 10 days
- Treatments recommended by WHO Expert Committee on the Control of Leishmaniases in 2010 as safe and effective treatments for visceral leishmaniasis in Asia (liposomal amphotericin B single or multiple dose, and all combinations tested in DNDi’s clinical trial)
- Supported policy change for the control and elimination of visceral leishmaniasis in highly endemic countries: Bangladesh, India, and Nepal
- Result of partnership in India with the Bihar State Health Society, GVK Biosciences, Indian Council of Medical Research, Kala Azar Medical Research Centre, Médecins Sans Frontières, National Vector Borne Disease Control Programme, and Rajendra Memorial Research Institute of Medical Sciences
- Result of partnership in Bangladesh with the International Centre for Diarrhoeal Disease Research, Médecins Sans Frontières, Ministry of Health and Family Welfare, Shaheed Suhrawardy Medical College and Hospital
‘Earlier the ward used to be full of visceral leishmaniasis patients because of the long 28-day treatment. But since single-dose liposomal amphotericin B has been included in the national treatment protocol, the face of the disease has changed dramatically. Now patients come, take treatment, and go home the same day. This is an effective treatment, and now with this the number of patients have come down.’
Nutan Kumari, Sadar Hospital in Hajipur, Bihar
News & resources
- 26 September 2019 - Field effectiveness of new visceral leishmaniasis regimens after 1 year following treatment within public health facilities in Bihar, India, PLOS Neglected Tropical Diseases
- 22 October 2018 - Field safety and effectiveness of new visceral leishmaniasis treatment regimens within public health facilities in Bihar, India, PLOS Neglected Tropical Diseases
- 12 June 2017 - Safety and efficacy of short course combination regimens with AmBisome®, miltefosine, paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh, PLOS Neglected Tropical Diseases
- 26 January 2017 - Investments in research and surveillance are needed to go beyond elimination and stop transmission of Leishmania in the Indian subcontinent, PLOS Negl Trop Dis
- 15 October 2014 - Study Results Support WHO Recommendations for Safe and Effective Kala-azar Treatments in Bangladesh
- 21 August 2014 - How far are we from visceral leishmaniasis elimination in Bangladesh? An assessment of epidemiological surveillance data, PLOS NTDs
- 7 November 2011 - Major Project Launched to Support India and Bangladesh’s National Control Programmes in Implementing New Treatments to Boost Kala-Azar Elimination Strategies
- 25 January 2011 - Study shows the safety and efficacy of combination treatment for visceral leishmaniasis in India
- 1 January 2011 - Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial, The Lancet
*Project cost includes direct and indirect costs, but it does not include in-kind contributions.
Get our latest news, personal stories, research articles, and job opportunities.